DE-THE-LYCRA-COMPANY
1.4.2021 22:04:04 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative solutions for the textile, apparel, and personal care industries, announces the appointment of Yafu Qiu, chairman of The LYCRA Company, and Julien Born, chief commercial officer of The LYCRA Company, as co-chief executive officers, effective April 1, 2021, following the retirement of David Trerotola. The co-ceo structure is intended to better implement The LYCRA Company’s new strategic development plan for the next five years and will bring greater operational focus and tap into each leader’s experience and skills in the areas most beneficial to the company to solidify its industry-leading position and drive its long-term success.
Mr. Trerotola served as the company’s chief executive officer since 2019, following the Ruyi Group’s acquisition of the business. Mr. Trerotola retires after 20 years of dedicated service to The LYCRA Company and its predecessor companies. He began his career in 1994 with DuPont.
“I want to thank Dave for his many contributions to The LYCRA Company,” said Yafu Qiu, chairman of The LYCRA Company, the company’s controlling shareholder. “Dave’s passion for the business was evident to me from the beginning, and I wish him all the best in this next phase of his journey with his wife and family. At my request, Dave will support a smooth transition of leadership and will be working with me and Julien over the next 60 days.”
Mr. Born, currently the company’s chief commercial officer, will serve as co-ceo and lead the overall operations of the company and implement its ambitious growth vision. Mr. Born joined the business in 2007 and, since 2018, led the company’s apparel business, where he managed the global commercial organization, helped strengthen R&D and innovation capabilities, and oversaw manufacturing assets. Mr. Born has also spent significant time in Asia, where he led that region over an eight-year period, with assignments in Shanghai and Hong Kong. Mr. Born has had a diverse 24-year career spent in the US, Europe and Asia, as both an executive in large multinational companies and as a business owner of a full-service corporate licensing agency. A native of Switzerland, Mr. Born holds a bachelor’s degree from Arizona State University’s W.P. Carey School of Business and a Swiss baccalaureate degree.
“The board has appointed Julien as The LYCRA Company’s next ceo,” said Mr. Qiu. “I am confident that Julien understands the opportunities and challenges facing the business and we are fully committed to supporting him and the entire leadership team on the new developments and performance growth of The LYCRA Company to help The LYCRA Company realize its full potential in 2021 and beyond.”
“I am excited for the opportunity to lead a tremendous team of colleagues at The LYCRA Company who are focused every day on creating value in the industries we serve via our unique brand portfolio, high-quality products, unparalleled innovation capabilities, and our global network of partners,” said Mr. Born. “I look forward to a close partnership with Chairman Qiu and the Ruyi Group to further develop our manufacturing capacity and accelerate the growth of our business, especially in China.”
Mr. Qiu, in addition to continuing as chairman of The LYCRA Company, will focus his co-ceo role on the company’s relationships with key stakeholders, board governance matters, strategic planning, and capital structure adjustments, including the strategy and timing of an initial public offering.
“The LYCRA Company is faced with many new challenges in a fast-developing world,” concluded Mr. Qiu. “We are taking this opportunity to appoint Mr. Born and other new management team members to work on a new strategy to further build our brand franchises, expand manufacturing capacity, develop more impactful innovations with our global value-chain partners, lead the industry in sustainability, and accelerate our digital transformation. I am confident that the new management team will be able to further strengthen the leadership role of The LYCRA Company in the apparel and personal care industries.”
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210401005877/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
